Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05340413
Title Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors SOLTI Breast Cancer Research Group

triple-receptor negative breast cancer

Her2-receptor negative breast cancer



Age Groups: adult | senior
Covered Countries ESP

Additional content available in CKB BOOST